concept · intermediate · partly written
Therapeutic window and therapeutic index
The gap between the exposure of a drug that gives its effect and the exposure that causes harm, judged on free drug.
Also called: therapeutic index, safety margin, hERG margin
In short
The window is arithmetic on exposure: the concentration that harms divided by the concentration that helps, both on free drug. Medicinal chemists raise the numerator by editing the molecule; clinicians and formulators move the denominator by dose and schedule. A margin is a screen with a known error rate, not a safety threshold. 123
Reported, not yet replicated
Worked case: the hERG margin more
hERG is a potassium channel that ends each heartbeat's electrical pulse; blocking it lengthens the QT interval and can tip into a chaotic rhythm called torsade de pointes. The margin divides the hERG IC50 by the free peak plasma concentration. The regulators did not adopt a number: the 2022 ICH question-and-answer text sets no numeric threshold, floors the free fraction at 1% where it measures below that, and asks each sponsor to compare against reference drugs run in the same protocol. Later checks look backwards at drug sets and none opened tests a margin prospectively. The 30-fold figure is therefore a chemist's screen: useful before a first dose, wrong in both directions on retrospective sets. 2435
Contested
Why free drug more
Plasma carries much of a drug bound to proteins; only the unbound fraction is available to act. In one set of 16 drugs, free margins separated drugs that caused torsade from drugs that only prolonged QT, while total margins overlapped. The same logic is why the unbound fraction is measured in the plasma protein binding assay. 6
Reported, not yet replicated
What attrition data do and do not say more
In an analysis of drug-indication pairs, 97% in oncology never reached approval and lack of efficacy and dose-limiting toxicities were the commonest causes. Across all areas the chance of passing from phase I to approval was 13.8%, and 3.4% in oncology. None of the sources opened counts "narrow window" as its own cause of failure, so how much of attrition a thin window explains is not measured here. 78
Reported, not yet replicated
The window in practice: it sets the starting dose and is judged over time more
ICH E4 ties the starting strategy to the width of the window: a wide gap supports a start near the plateau, a narrow gap a low start with titration, and large variability (non-linear kinetics, polymorphic metabolism, interactions) argues for a lower start. It also says drugs have often been first marketed at what were later recognised as excessive doses. In patients the practical window is narrower than a single toxicity grade suggests, because FDA's 2024 guidance counts persistent low-grade symptoms and the proportion able to take all planned doses. Of 54 FDA-approved oncology small molecules, 28% were approved at the maximum tolerated dose and those had the highest median dose-reduction rate (28.0% against 10.5% for labels below the maximum studied dose). For zolpidem FDA required lower recommended doses for women in 2013 after blood-level data; that change is contested. This is published practice described for understanding, not dosing guidance. 9101112
Reported, not yet replicated
His question: why does a controllable dose matter? more
He said: "You continue narrowing down the curve. You maybe do dose response. Now you have how potent the compound is, and you're looking for something that you can control the dosage of to get a desired effect, because actually, I'm not sure why." His words, kept as he said them. The sourced answer is in the sections above: the dose sets exposure, exposure sets both the effect and the harm, and the window decides how much patient-to-patient scatter in exposure the drug can take. 13
Amit's hypothesis
Plain answer
A drug has a window: the exposure that gives the effect sits below the exposure that causes unacceptable harm. The therapeutic index is the highest exposure without toxicity divided by the exposure that gives the effect. Exposure here means the concentration that reaches the target tissue, which is the unbound (free) drug, not the total in plasma. 12
Reported, not yet replicated
Why it matters
More potency is not the goal in itself. Potency lowers the dose needed for the effect; what decides whether the drug can be used is whether the effect and the harm stay separated at the exposure patients actually reach, and exposure varies between patients. A compound whose off-target harm begins close to the concentration it needs on target has little room for that variation. This is our reasoning from the sources, not a measured finding. 12
Our inference
Real numbers
hERG margin in the drug literature
Across 100 drugs reviewed (hERG and free-concentration data available for 52), the ratio of hERG IC50 to free effective plasma concentration was 0.1 to 31 for class Ia/III antiarrhythmics (amiodarone excepted) and 0.31 to 13 for drugs withdrawn for torsade de pointes; most drugs with no reports were more than 30-fold apart, verapamil (1.7) an exception. The authors wrote that a 30-fold margin "may suffice" for drugs in clinical evaluation. Abstract read. 2
Reported, not yet replicated
Free against total drug (16 drugs, one company)
Free margins were 0.7 to 28 for drugs causing torsade against 42 to 286 for drugs that prolong QT without torsade, while total margins overlapped (0.07 to 30.2 against 0.6 to 27). Cutoffs were chosen after seeing the data. 6
Reported, not yet replicated
Channel block at a margin of 30
One modelling group reaches about 3% of channels blocked at a 30-fold margin, which it calls highly stringent; this is its model, not a measurement. 14
Reported, not yet replicated
The error rate of the number 30
On 28 drugs of the CiPA set a threshold of 30 gave 27% false negatives and 33% false positives; a threshold of 300 gave 2% and 67%. In a 150-drug database, 28 of 43 drugs that prolonged QT in thorough clinical studies showed no positive signal in any of three nonclinical assays within 30-fold exposure; for hERG alone sensitivity at 30-fold was about 50%. 35
Reported, not yet replicated
Still open here
- No source opened measures how much of clinical attrition a narrow window explains.
- The later revision of the ICH E14/S7B text was not opened.
- The nirmatrelvir record shows a dose target set from cell potency and checked against patient troughs; the general account of dose selection is now in questions/how-a-dose-and-schedule-are-chosen.
- Whether dose optimisation under the 2024 FDA oncology guidance widened the realised window.
Not yet written: Equation.
Linked from
Sources
- Muller, Patrick Y., Milton, Mark N.. The determination and interpretation of the therapeutic index in drug development. Nature Reviews Drug Discovery (2012). paper; opened 2026-11-17 all records citing this
- REDFERN, W, CARLSSON, L, DAVIS, A, et al.. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovascular Research (2003). paper; opened 2026-11-17 all records citing this
- Ridder, Bradley J., Leishman, Derek J., Bridgland-Taylor, Matthew, et al.. A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigm. Toxicology and Applied Pharmacology (2020). paper; opened 2026-11-17 all records citing this
- International Council for Harmonisation. ICH E14/S7B Implementation Working Group: Questions and Answers (Step 4, 21 February 2022). ICH database (2022). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
- Valentin, Jean-Pierre, Hoffmann, Peter, Ortemann-Renon, Catherine, et al.. The Challenges of Predicting Drug-Induced QTc Prolongation in Humans. Toxicological Sciences (2022). paper; opened 2026-11-17 all records citing this
- Yao, X, Anderson, D L, Ross, S A, et al.. Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea‐pig model. British Journal of Pharmacology (2008). paper; opened 2026-11-17 all records citing this
- Lin, Ann, Giuliano, Christopher J., Palladino, Ann, et al.. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Science Translational Medicine (2019). paper; opened 2026-11-17 all records citing this
- Wong, Chi Heem, Siah, Kien Wei, Lo, Andrew W. Estimation of clinical trial success rates and related parameters. Biostatistics (2019). paper; opened 2026-11-17 all records citing this
- ICH. ICH E4: Dose-Response Information to Support Drug Registration. ICH (1994). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
- US FDA. Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases (final guidance). US FDA (2024). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
- Collins KP, Yin D, Pithavala YK, et al.. Landscape analysis of adverse events and dose intensity for FDA approved oncology small molecules. Cancer Chemother Pharmacol (2025). paper; opened 2026-11-17 all records citing this
- US FDA. FDA Drug Safety Communication: Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem. US FDA (2013). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
- Amit's dictation of 2026-11-17: what the atlas must contain. Kept in the atlas repository; not published.
- Wan, Hongbin, Selvaggio, Gianluca, Pearlstein, Robert A.. Toward in vivo-relevant hERG safety assessment and mitigation strategies based on relationships between non-equilibrium blocker binding, three-dimensional channel-blocker interactions, dynamic occupancy, dynamic exposure, and cellular arrhythmia. PLOS ONE (2020). paper; opened 2026-11-17 all records citing this
- Demetri GD, Wang Y, Wehrle E, et al.. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol (2009). paper; opened 2026-11-17 all records citing this
- Suh HY, Peck CC, Yu KS, et al.. Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013. Drug Des Devel Ther (2016). paper; opened 2026-11-17 all records citing this
Where it sits on the map
History of this record (2)
This record has been changed 2 times, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.
- Status
- partly written
- Last updated
- 2026-11-17
- Record
- content/concepts/therapeutic-window.json